1. Medtech Insight
  2. >>Business
  3. >>Deals

Cantel Medical Snapped Up By Steris For $3.6Bn

 
• By Phil Greenfield

The deal combines two of the largest providers of sterilization and infection-prevention products to create a $4bn-plus-revenue business.

Medical laboratory technician holding a set of sterile disposable instruments
sterilized instruments • Source: shutterstock.com

The acquisition of Cantel Medical by Steris, announced on 12 January, will create a giant medical device sterilization and infection control company. The stock deal values Cantel at around $3.6bn, or $84.66 a share.

The combined company will offer cost-cutting opportunities and expand Steris' reach into the dental market, where Cantel provides a large range of infection control products. It will also help both...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By Marion Webb

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

Bone Surgery Startup Surgify Medical Raises $7.9m

 
• By Natasha Barrow

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.